At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
DDP +2 moredrug
Likely dose
DDP 25 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.
In Brief
A Phase 2 clinical trial evaluating SMART, DDP, and 1 other intervention for Esophageal Squamous Cell Carcinoma. Completed, enrolled 42 participants across 1 site.
Detailed Summary
This Prospective, single-arm Phase Ⅱ study is to determine the efficacy and safety of Once-daily Simultaneous Modulated Accelerated Radiotherapy combined with S-1/DDP for geratic esophageal squamous cell carcinoma patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Squamous Cell Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedNov 2015
Primary CompletionAug 2020
TodayJul 2026
First PostedNov 17, 2015
Enrollment StartJul 1, 2015
Primary CompletionAug 1, 2020
TodayJul 1, 2026
Enrollment to primary: 5.1 yearsPosted 10.6 years ago
Interventions
SMARTradiation
Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
DDPdrug
DDP(25 mg/m2.qw) for six weeks.
S-1drug
S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy